Helen Kim, MBA

Ms. Kim brings over 30 years of highly valuable biotech industry expertise to NKMax.  Most recently, Ms. Kim was named as the managing director of VIDA Ventures. She was formerly the EVP of Business Development at Kite Pharma, Inc.  and was instrumental in leading the acquisition of Kite Pharma by Gilead. Previously she was Chief Business Officer at NGM Biopharmaceuticals. Prior to NGM she was the CEO and President of Kosan Biosciences which was successfully purchased by Bristol-Myers Squibb.  Ms. Kim has held several executive management positions at Affymax, Onyx Pharmaceuticals, and Chiron Corporation.